AU · rank #2 · 2026-10-19
ATEC
NASDAQ · $1.74B (USD)
The exact numbers the algorithm saw.
| Composite score Z-score blend of all factors below. | 2.925 |
|---|---|
| EPS revisions (30d) Change in consensus EPS estimate over the past 30 days ($/share). | +$0.01 |
| Net revisions (30d) Number of analysts revising upward minus downward. | 1 |
| Insider signal (90d) $1,013,150 across 1 unique buyers. | 3.000 |
| Analyst upside Consensus target $15.79 | +50.9% |
| Momentum acceleration 3-month minus 12-month momentum. | +33.46% |
| Analyst rating 5 = Strong Buy, 1 = Strong Sell. | 4.79 |
| Gross margin TTM | +70.8% |
| 52w high | $23.29 |
| Market cap (USD) | $1.74B |
The AI research card
Independent qualitative review of each pick before the order is placed. On the rare day the research service is unavailable, the paper book trades on the quant ranking alone and no card appears here.
Summary
Alphatec Holdings Inc develops and commercializes integrated spinal surgery solutions, including implants, biologics, SafeOp neuromonitoring, EOS full-body imaging, and the Valence navigation and robotics platform.
Rationale
The 50.9% analyst upside signal is supported by solid fundamental execution, including 15% revenue growth, 24% net-new surgeon growth, 72.5% gross margins, and an upgraded 2026 EBITDA guidance of $140 million.
Material risks
- 1Dominant spine competitors like Medtronic, Globus Medical, and Stryker could aggressively bundle competing navigation, robotics, and implant platforms to limit adoption of EOS Insight and Valence.
- 2A heavy debt load of $510.7 million versus $119 million in cash leaves the company vulnerable to execution delays or lower-than-projected free cash flow conversion.
AI verdict council
Each pick is reviewed independently by 3 models before any order. 2 of 3 voted to proceed.